ENDRA Life Sciences Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical crossroads, where a potentially transformative technology is trapped behind a wall of severe liquidity and regulatory constraints. While the market for liver fat quantification is expanding rapidly due to the success of GLP-1 therapies, ENDRA lacks the capital to execute the clinical trials required for U.S. market entry. The shift toward a subscription model and the adoption of a digital asset treasury are bold attempts to pivot the company's valuation, but they do not address the immediate need for a viable, approved product. Investors are now faced with a binary outcome. Either ENDRA secures a strategic partner or a significant capital infusion to restart its FDA pathway, or it faces delisting and potential insolvency. The board's decision to evaluate strategic alternatives suggests that a merger or asset sale may be the most realistic path to preserving any remaining shareholder value, as the internal resources to reach commercialization appear exhausted.